You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK):OSEMITAMAB (TST001)聯合納武利尤單抗與化療或聯合化療作為胃癌或胃食管連接部癌患者一線治療的中國II期臨牀研究完成C和G隊列患者入組
格隆匯 05-03 06:42

格隆匯5月3日丨創勝集團-B(06628.HK)發佈公吿,其具有增強ADCC活性的高親和力人源化抗CLDN18.2單克隆抗體Osemitamab (TST001)作為CLDN18.2表達的胃癌或胃食管連接部癌一線治療的中國II期臨牀試驗(Transtar-102,NCT04495296),已完成C隊列和G隊列的患者入組。G隊列旨在評估Osemitamab (TST001)與納武利尤單抗、卡培他濱和奧沙利鉑(CAPOX)的聯用。而C隊列旨在探索Osemitamab (TST001)與CAPOX的聯用。臨牀研究正在美國進行中。

公司全球藥物開發執行副總裁、首席醫學官Caroline Germa博士表示:“這些隊列入組完成標誌着公司的一個重要里程碑,為Osemitamab (TST001)的全球 III期臨牀試驗和符合監管機構的劑量優化要求奠定了基礎,同時還提供了關於 CLDN18.2表達與Osemitamab (TST001)相關療效的重要預測信息,尤其是在中低表達水平的患者中。我們期待在不久的將來公佈這些臨牀數據。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account